TG Therapeutics, Inc. (TGTX) Financials
Key financial figures for TG Therapeutics, Inc. (Q2 2026).
TG Therapeutics Inc. reported revenue of $240.3 million for Q2 FY2026, up 70.3% from the same period a year earlier. Net income was $7.8 million, or $0.05 per share. Operating margin came to 9.02%, against 24.69% a year earlier. Free cash flow for the period was $21.0 million. Across the last 5 reported quarters, quarterly revenue has risen from $141.1 million in Q2 FY2025 to $240.3 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for TG Therapeutics Inc. are on the SentiSense financials page.
- Revenue
- $240M
- Net Income
- $8M
- EPS
- $0.05
- Total Assets
- $1.6B
- Operating Cash Flow
- $39M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $240M | $8M | $0.05 | 9.02% | $21M |
| Q1 FY2026 | $205M | $20M | $0.12 | 16.98% | -$18M |
| Q4 FY2025 | $193M | $23M | $0.14 | 26.22% | $20M |
| Q3 FY2025 | $162M | $391M | $2.43 | 18.16% | -$23M |
| Q2 FY2025 | $141M | $28M | $0.17 | 24.69% | $7M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $616M | $447M | $2.77 | 20.01% | -$25M |
| FY2024 | $329M | $23M | $0.15 | 12.74% | -$41M |
| FY2023 | $234M | $13M | $0.09 | 8.83% | -$31M |
Frequently asked questions
What was TG Therapeutics Inc.'s revenue last quarter?
TG Therapeutics Inc. reported revenue of $240.3 million for Q2 FY2026, up 70.3% from the same period a year earlier.
Is TG Therapeutics Inc. profitable?
Yes. TG Therapeutics Inc. reported net income of $7.8 million for Q2 FY2026, a net margin of 3.24% on revenue.
How has TG Therapeutics Inc.'s margin trended?
Operating margin was 9.02% in Q2 FY2026, compared with 24.69% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did TG Therapeutics Inc. generate?
TG Therapeutics Inc. generated free cash flow of $21.0 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for TG Therapeutics, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.